Sorafenib
- All
- News
-
Natco Pharma's Partner Mylan Inc Gets USFDA Approval For Cancer Drug
- Friday June 3, 2016
- Business | Press Trust of India
Natco Pharma's marketing partner Mylan Inc has received a tentative approval from the USFDA for abbreviated new drug application (ANDA) for Sorafenib tablets.
- www.ndtv.com/business
-
Natco Jumps 9% As Partner Mylan Inc Gets USFDA Nod
- Friday June 3, 2016
- Business | Press Trust of India
Natco Pharma shares surged nearly 9 per cent on Friday after the company said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets, used for cancer treatment, in the American market.
- www.ndtv.com/business
-
Natco Pharma's US Partner Mylan Files Application With USFDA
- Wednesday February 11, 2015
- Business | Press Trust of India
The company's marketing partner Mylan Inc has filed an abbreviated new drug application (ANDA) for Sorafenib tablets in the strength of 200mg with the US Food and Drug Administration (USFDA), Natco Pharma said in a filing to the BSE on Wednesday.
- www.ndtv.com/business
-
Natco Pharma's Partner Mylan Inc Gets USFDA Approval For Cancer Drug
- Friday June 3, 2016
- Business | Press Trust of India
Natco Pharma's marketing partner Mylan Inc has received a tentative approval from the USFDA for abbreviated new drug application (ANDA) for Sorafenib tablets.
- www.ndtv.com/business
-
Natco Jumps 9% As Partner Mylan Inc Gets USFDA Nod
- Friday June 3, 2016
- Business | Press Trust of India
Natco Pharma shares surged nearly 9 per cent on Friday after the company said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets, used for cancer treatment, in the American market.
- www.ndtv.com/business
-
Natco Pharma's US Partner Mylan Files Application With USFDA
- Wednesday February 11, 2015
- Business | Press Trust of India
The company's marketing partner Mylan Inc has filed an abbreviated new drug application (ANDA) for Sorafenib tablets in the strength of 200mg with the US Food and Drug Administration (USFDA), Natco Pharma said in a filing to the BSE on Wednesday.
- www.ndtv.com/business